NZ514478A - A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate - Google Patents
A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonateInfo
- Publication number
- NZ514478A NZ514478A NZ514478A NZ51447800A NZ514478A NZ 514478 A NZ514478 A NZ 514478A NZ 514478 A NZ514478 A NZ 514478A NZ 51447800 A NZ51447800 A NZ 51447800A NZ 514478 A NZ514478 A NZ 514478A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bisphosphonate
- pharmaceutical formulation
- additive agent
- agent providing
- enhanced absorption
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901272A SE9901272D0 (en) | 1999-04-09 | 1999-04-09 | New improved formulation |
PCT/SE2000/000664 WO2000061111A1 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ514478A true NZ514478A (en) | 2004-01-30 |
Family
ID=20415159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ514478A NZ514478A (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1171097A1 (en) |
JP (1) | JP2002541185A (en) |
KR (1) | KR20010104389A (en) |
AU (1) | AU4161900A (en) |
CA (1) | CA2364659A1 (en) |
IL (1) | IL145506A0 (en) |
NO (1) | NO20014895L (en) |
NZ (1) | NZ514478A (en) |
SE (1) | SE9901272D0 (en) |
WO (1) | WO2000061111A1 (en) |
ZA (1) | ZA200108260B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
AU2001251432A1 (en) | 2000-04-07 | 2001-10-23 | The Board Of Regents Of The University Of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity |
WO2001085217A1 (en) * | 2000-05-05 | 2001-11-15 | F. Hoffmann-La Roche Ag | Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts |
JP4354698B2 (en) | 2001-03-01 | 2009-10-28 | エミスフェアー・テクノロジーズ・インク | Bisphosphonate delivery composition |
AU2002330692A1 (en) | 2001-07-02 | 2003-01-21 | Elan Corporation, Plc. | Delivery of a bioactive material |
ES2532393T3 (en) | 2002-05-10 | 2015-03-26 | F. Hoffmann-La Roche Ag | Bisphosphonic acids for treatment and prevention of osteoporosis |
NZ536273A (en) | 2002-12-20 | 2007-08-31 | Hoffmann La Roche | High dose ibandronate formulation |
ATE402942T1 (en) * | 2003-01-17 | 2008-08-15 | Teva Pharma | METHOD FOR REDUCING IRON CONTENT IN RISEDRONATE SODIUM |
GB0310919D0 (en) * | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
WO2004110458A1 (en) * | 2003-05-16 | 2004-12-23 | Board Of Regents, The University Of Texas System | Phenothiazine enantiomers as agents for the prevention of bone loss |
US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
ATE475412T1 (en) * | 2004-05-24 | 2010-08-15 | Warner Chilcott Co Llc | ENTERIC SOLID ORAL DOSAGE FORM OF A BISPHOSPHONATE WITH A CHELATE |
US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
KR100815040B1 (en) * | 2005-01-31 | 2008-03-18 | 주식회사종근당 | Pharmaceutical compositions containing bisphosphonate for improving oral absorption |
NO20053519L (en) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Use of compounds comprising fatty acids |
EP2007397B1 (en) | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
GB0616794D0 (en) | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
TW200950799A (en) | 2008-05-07 | 2009-12-16 | Merrion Res Iii Ltd | Compositions of GnRH related compounds and processes of preparation |
CA2731769C (en) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
KR101631243B1 (en) * | 2009-05-13 | 2016-06-17 | 신일제약주식회사 | Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same |
EP3295935B1 (en) | 2009-07-31 | 2020-07-22 | Grünenthal GmbH | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
FR2954320B1 (en) | 2009-12-17 | 2012-06-15 | Cll Pharma | SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
CA2819234A1 (en) | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
KR20120105738A (en) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | An enteric-coated oral formulation |
JP5874545B2 (en) * | 2011-06-20 | 2016-03-02 | アステラス製薬株式会社 | Pharmaceutical composition for oral administration |
WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
US20180161401A1 (en) * | 2015-07-06 | 2018-06-14 | Zheng Xin Dong | Novel Formulations of PTHrP Analogue |
EP3455229B1 (en) | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
CN112972400A (en) * | 2021-03-09 | 2021-06-18 | 华侨大学 | Rapidly disintegrable minodronic acid granules and preparation method thereof |
KR20240013402A (en) * | 2022-07-22 | 2024-01-30 | 주식회사 아이큐어비앤피 | Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
EP0550385A1 (en) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers |
TW237386B (en) * | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
SE501389C2 (en) * | 1992-04-24 | 1995-01-30 | Leiras Oy | Pharmaceutical preparation and process for its preparation |
ES2065313T5 (en) * | 1993-05-15 | 2004-01-01 | Roche Diagnostics Gmbh | TABLET WITH IMPROVED BIODISPONIBILITY CONTAINING DICHLOROMETILENDIFOSFONICO ACID AS ACTIVE SUBSTANCE. |
IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
FI109088B (en) * | 1997-09-19 | 2002-05-31 | Leiras Oy | Tablet and process for its preparation |
SE9703691D0 (en) * | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-04-09 SE SE9901272A patent/SE9901272D0/en unknown
-
2000
- 2000-04-06 KR KR1020017012793A patent/KR20010104389A/en not_active Application Discontinuation
- 2000-04-06 WO PCT/SE2000/000664 patent/WO2000061111A1/en active Search and Examination
- 2000-04-06 AU AU41619/00A patent/AU4161900A/en not_active Abandoned
- 2000-04-06 NZ NZ514478A patent/NZ514478A/en unknown
- 2000-04-06 EP EP00921288A patent/EP1171097A1/en not_active Withdrawn
- 2000-04-06 JP JP2000610444A patent/JP2002541185A/en active Pending
- 2000-04-06 CA CA002364659A patent/CA2364659A1/en not_active Abandoned
- 2000-04-06 IL IL14550600A patent/IL145506A0/en unknown
-
2001
- 2001-10-08 NO NO20014895A patent/NO20014895L/en not_active Application Discontinuation
- 2001-10-08 ZA ZA200108260A patent/ZA200108260B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20014895L (en) | 2001-12-10 |
NO20014895D0 (en) | 2001-10-08 |
ZA200108260B (en) | 2003-03-26 |
SE9901272D0 (en) | 1999-04-09 |
KR20010104389A (en) | 2001-11-24 |
EP1171097A1 (en) | 2002-01-16 |
IL145506A0 (en) | 2002-06-30 |
CA2364659A1 (en) | 2000-10-19 |
AU4161900A (en) | 2000-11-14 |
WO2000061111A1 (en) | 2000-10-19 |
JP2002541185A (en) | 2002-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ514478A (en) | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate | |
EP1310259A3 (en) | Formulation comprising a biphosphonate and an absorption enhancing agent for the treatment of osteoporosis | |
SI1663185T1 (en) | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | |
TR200101103T2 (en) | Controlled release pharmaceutical formulations containing CGMP PDE-Inhibitor | |
NZ294933A (en) | Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
SI1880744T1 (en) | Bisphosphonic acids for the treatment and prevention of osteoporosis | |
MY118151A (en) | Pharmaceutical formulations containing voriconazole. | |
DE60038038D1 (en) | Phosphonatverbindungen | |
ATE232874T1 (en) | PROSTAGLANDIN CONJUGATES FOR THE TREATMENT OF BONE DISEASES | |
HUP0004271A2 (en) | Compositions comprising amylin or amylin agonist for treating obesity | |
ZA200110504B (en) | Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria. | |
AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
AUPQ127399A0 (en) | Compositions and methods for treating or preventing osteoporosis | |
HU9501121D0 (en) | Pharmaceutical composition for treating osteoporosis | |
ZA98214B (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1. | |
WO2001030333A3 (en) | Tissue factor antagonists and methods of use thereof | |
GB9804886D0 (en) | Therapeutic combination | |
AU2003211610A1 (en) | Pharmaceutical compositions for the treatment or prevention of osteoporosis | |
ZA97252B (en) | Compositions for the prevention and treatment of osteoporosis. | |
AP2001002369A0 (en) | Pharmaceutical complex. | |
TWI262791B (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
EP1147773A4 (en) | Medicinal compositions for treating osseous lesion in multiple myeloma | |
AU4546900A (en) | Estrogen receptors and bone | |
MXPA03006468A (en) | Compositions for prevention or treatment of hepatopathy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
PSEA | Patent sealed |